KPV Research Overview (also known as Lys-Pro-Val tripeptide, α-MSH (11-13), α-MSH tripeptide, KPV)
A tripeptide (Lys-Pro-Val) derived from the C-terminal of alpha-melanocyte stimulating hormone (α-MSH). Studied for potent anti-inflammatory effects across skin, gut, and systemic pathways through melanocortin receptor modulation. Research interest includes inflammatory bowel disease models, skin inflammation, and systemic inflammatory regulation.
For the regulatory discussion specific to KPV and other compounds considered by the FDA advisory panel, read FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding.
What Is KPV?
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of α-Melanocyte Stimulating Hormone (α-MSH). It retains α-MSH's anti-inflammatory and melanocortin receptor-binding properties in a minimally sized, highly stable three-amino-acid peptide. Its small size gives it favorable penetration properties — including ability to reach colonic mucosal cells when given orally — that full-length α-MSH lacks.
Mechanism of Action
KPV exerts its anti-inflammatory effects through MC1R and MC3R (melanocortin receptors 1 and 3) activation, which suppresses NF-κB signaling — the master transcription factor driving inflammation — reducing production of TNF-α, IL-6, IL-8, and other pro-inflammatory cytokines. It also promotes regulatory and anti-inflammatory phenotypes in macrophages and T-cells.
IBD and Skin Research
KPV has been studied extensively for IBD because its small size allows it to survive the GI tract and reach inflamed colonic mucosa when taken orally or administered via enema. Animal studies using murine colitis models demonstrate dramatically reduced colonic inflammation and improved colon histology scores. For skin conditions including psoriasis and atopic dermatitis, KPV's melanocortin receptor activation reduces keratinocyte-driven inflammation and promotes healing responses.
Quick Reference
| Literature-Reported Dose Range | 200-500mcg (0.2-0.5mL at 1mg/mL concentration) |
| Literature-Reported Frequency | 1-2 times daily depending on condition severity |
| Literature-Reported Cycle Length | 4-8 weeks |
| Literature-Reported Washout | 2-4 weeks to assess baseline inflammation |
| Storage | Refrigerate after reconstitution, stable for 30-45 days |
| Sites Reported in Studies | Subcutaneous: Abdomen (preferred for gut issues), thigh, upper arm |
| Timing | Can be taken any time; some prefer morning for anti-inflammatory effects |
Research Indications
Inflammation
Systemic Inflammation
Reduces circulating inflammatory markers like TNF-α and IL-6
Autoimmune Modulation
May help balance overactive immune responses
Joint Inflammation
Potential benefits for inflammatory arthritis
Gut Health
IBD Support
Shows promise for Crohn's disease and ulcerative colitis
Intestinal Barrier
Helps repair and maintain gut barrier integrity
Microbiome Balance
Selective antimicrobial effects preserve beneficial bacteria
Immune Function
Cytokine Regulation
Normalizes inflammatory cytokine production
Immune Balance
Helps shift from Th1/Th17 to regulatory T cell responses
Infection Response
Maintains antimicrobial defense while reducing inflammation
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General Anti-Inflammatory | 200-300mcg | Once daily | SubQ |
| Active Inflammation | 250mcg | Twice daily | SubQ |
| Autoimmune Support | 500mcg | Once daily | SubQ |
| Acute Flare-ups | 500mcg | Twice daily for 1 week then reduce | SubQ |
Timing
Can be taken any time; some prefer morning for anti-inflammatory effects. Typical onset: initial effects 3-7 days, significant improvement 2-4 weeks, optimal results 6-8 weeks.
Peptide Interactions
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Complementary gut healing mechanisms - BPC-157 promotes tissue repair while KPV reduces inflammation
Both are antimicrobial peptides - KPV focuses on inflammation while LL-37 on direct antimicrobial action
Excellent combination for skin health - GHK-Cu promotes collagen while KPV reduces inflammation
KPV is derived from α-MSH like MT-II but without tanning effects - using both is unnecessary
Reported Research Timeline
01Day 1–3 (reported in cited studies): subtle reduction in inflammation, improved energy
02Week 1 (reported in cited studies): noticeable decrease in inflammatory symptoms
03Week 2–3 (reported in cited studies): improved gut function, reduced pain/swelling
04Week 4 (reported in cited studies): significant improvement in target condition
05Week 6–8 (reported in cited studies): sustained anti-inflammatory benefits, improved quality of life
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Excellent safety profile with minimal side effects
Does not cause immunosuppression like steroids
No melanin production or tanning effects
May temporarily reduce inflammation-related symptoms
Monitor for signs of infection (rare)
Generally well-tolerated even at higher doses
Seek Medical Attention If:
Signs of infection (fever, chills) - very rare
Severe injection site reactions
Paradoxical increase in inflammation
Any allergic reaction symptoms
Unusual fatigue or weakness
Quality Indicators
Verified Marker
High purity essential
KPV should be >98% pure due to its use in inflammatory conditions
Verified Marker
Clear solution
Properly dissolved KPV is completely clear and colorless
Verified Marker
Stable peptide
Small size makes KPV relatively stable compared to larger peptides
Acceptable Range
Proper pH
Solution should be pH 5.5-7 for optimal stability
Quality Concern
Visible particles
Any cloudiness or particles indicate contamination or degradation
Quality Concern
Yellow coloration
Yellowing indicates oxidation and loss of potency
Research Citations
- Antimicrobial Properties Against Gut Pathogens (2022)
In vitro | Multiple bacterial strains | MIC determination - KPV for Psoriasis and Dermatitis (2021)
Human cells + Animal model | Topical application | 4 weeks - Anti-Inflammatory Mechanisms of KPV (2020)
In vitro | Various concentrations | Cell culture studies - KPV in Inflammatory Bowel Disease Models (2019)
Animal model | Oral and injection | 14 days | Colitis model - Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin
Pawar K, Kolli CS, Rangari VK, 2017, J Pharm Sci - Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway
Sung J, Ju SY, Park S, 2025, Tissue Cell - Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers
Cheng J, Wu P, Li C, 2026, Sci Adv - The neuroimmunomodulatory peptide alpha-MSH
Ichiyama T, Sato S, Okada K, 2000, Ann N Y Acad Sci - Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model
Laroui H, Dalmasso G, Nguyen HT, 2010, Gastroenterology
Research Focus
Anti-inflammatory, Gut healing, Skin inflammation, Melanocortin receptor, IBD, Wound healing
Verified Vendors Carrying KPV
Frequently Asked Questions
What should researchers watch for with KPV?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with KPV?
Day 1–3 (reported in cited studies): subtle reduction in inflammation, improved energy
How is KPV typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →